Literature DB >> 11260417

Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels.

S Jones1, C J Holmes, R T Krediet, R Mackenzie, D Faict, A Tranaeus, J D Williams, G A Coles, N Topley.   

Abstract

BACKGROUND: In a randomized, controlled trial comparing a pH neutral, bicarbonate/lactate (B/L)-buffered PD solution to conventional acidic, lactate-buffered solution (C), the overnight dialysate levels of markers of inflammation/wound healing [hyaluronic acid (HA)], mesothelial cell mass/membrane integrity [cancer antigen 125 (CA125)], and fibrosis [transforming growth factor-beta1 (TGF-beta1) and procollagen I peptides (PICP)] were assessed over a six-month treatment period.
METHODS: One hundred six patients were randomized (2:1) to either the B/L group or C group. Overnight effluents were collected at entry into the study (time = 0 all patients on control solution) and then at three and six months after randomization. Aliquots were filtered, stored frozen, and assayed for HA, CA125, TGF-beta1, and PICP. Differences between groups were assessed by repeated-measures analysis of variance for unbalanced data using the SAS procedure MIXED.
RESULTS: In patients treated with B/L, there was a significant (P = 0.03) increase in CA125 after six months compared with time = 0 (19.76 +/- 11.8 vs. 24.4 +/- 13.8 U/mL; mean +/- SD; N = 51). In the same group of patients, HA levels were significantly decreased at both three and six months in the B/L-treated group (time = 0, 336.0 +/- 195.2; time = 3 months, 250.6 +/- 167.6; and time = 6 months, 290.5 +/- 224.6 ng/mL; mean +/- SD; P = 0.006, N = 47 and P = 0.003, N = 48, respectively). No significant changes in CA125 or HA levels were observed in the control group. There were no significant changes observed in the levels of PICP or TGF-beta1 in the B/L or C group over the six-month treatment period.
CONCLUSIONS: These results suggest that continuous therapy with the B/L solutions modulates the levels of putative markers of peritoneal membrane integrity and inflammation. In the long term, this may positively impact the peritoneal membrane, increasing its life as a dialyzing organ.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11260417     DOI: 10.1046/j.1523-1755.2001.0590041529.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  25 in total

1.  Dialysate CA125 levels after 5 years on continuous peritoneal dialysis.

Authors:  Cengiz Candan; Pınar Turhan; Lale Sever; Mahmut Civilibal; Nur Canpolat; Salim Caliskan; Ozgur Kasapcopur; Nil Arisoy
Journal:  Pediatr Nephrol       Date:  2011-01-29       Impact factor: 3.714

2.  Peritoneal dialysate effluent and serum CA125 concentrations in stable peritoneal dialysis patients.

Authors:  Lynn Redahan; Andrew Davenport
Journal:  J Nephrol       Date:  2015-11-30       Impact factor: 3.902

3.  Impact of a low-glucose peritoneal dialysis regimen on fibrosis and inflammation biomarkers.

Authors:  Susan Yung; Sing Leung Lui; Chris K F Ng; Andrew Yim; Maggie K M Ma; Kin Yee Lo; Chik Cheung Chow; Kwok Hong Chu; Wai Leung Chak; Man Fai Lam; Chun Yu Yung; Terence P S Yip; Sunny Wong; Colin S O Tang; Flora S K Ng; Tak Mao Chan
Journal:  Perit Dial Int       Date:  2015 Mar-Apr       Impact factor: 1.756

4.  Is It Beneficial to Convert to a Neutral-pH Bicarbonate/Lactate-Buffered PD Solution in Long-Term CAPD Patients? A Single-Center Prospective Study.

Authors:  Tae-Hyun Yoo; Mi Jung Lee; Hyung Jung Oh; Jung Tak Park; Seung Hyeok Han; Shin-Wook Kang; Dae Suk Han
Journal:  Perit Dial Int       Date:  2015 May-Jun       Impact factor: 1.756

5.  Morphological characteristics in peritoneum in patients with neutral peritoneal dialysis solution.

Authors:  Chieko Hamada; Kazuho Honda; Kunio Kawanishi; Hirotaka Nakamoto; Yasuhiko Ito; Tsutomu Sakurada; Yudo Tanno; Toru Mizumasa; Masanobu Miyazaki; Misaki Moriishi; Masaaki Nakayama
Journal:  J Artif Organs       Date:  2015-02-14       Impact factor: 1.731

6.  Characterization of peritoneal dialysis effluent-derived cells: diagnosis of peritoneal integrity.

Authors:  Yo Higashi; Koji Abe; Tomoaki Kuzumoto; Takuya Hara; Keiichi Miyamoto; Tomohiro Murata; Eiji Ishikawa; Shinsuke Nomura; Takashi Horiuchi
Journal:  J Artif Organs       Date:  2012-12-30       Impact factor: 1.731

7.  Hyperbranched polyglycerol: a future alternative to polyglucose in peritoneal dialysis fluids?

Authors:  Bengt Rippe
Journal:  Perit Dial Int       Date:  2013 Jan-Feb       Impact factor: 1.756

8.  Biocompatible Dialysis Solutions Preserve Peritoneal Mesothelial Cell and Vessel Wall Integrity. A Case-Control Study on Human Biopsies.

Authors:  Gloria del Peso; José Antonio Jiménez-Heffernan; Rafael Selgas; César Remón; Marta Ossorio; Antonio Fernández-Perpén; José Antonio Sánchez-Tomero; Antonio Cirugeda; Erika de Sousa; Pilar Sandoval; Raquel Díaz; Manuel López-Cabrera; María Auxiliadora Bajo
Journal:  Perit Dial Int       Date:  2015-10-16       Impact factor: 1.756

Review 9.  Effect of biocompatible peritoneal dialysis solution on residual renal function: a systematic review of randomized controlled trials.

Authors:  Eun-Young Seo; Sook Hee An; Jang-Hee Cho; Hae Sun Suh; Sun-Hee Park; Hyesun Gwak; Yong-Lim Kim; Hunjoo Ha
Journal:  Perit Dial Int       Date:  2014-09-02       Impact factor: 1.756

10.  Effect of balance Solution on the Peritoneal Membrane in Automated Peritoneal Dialysis.

Authors:  Tatiana De Los Ríos; Juan Pérez-Martínez; Jose Portoles; Monika Lichodziejewska-Niemierko; Maite Rivera; Michał Nowicki; Andrzej Książek; Ana María Tato; Christine Bohnhorst; Mariano Feriani
Journal:  Perit Dial Int       Date:  2016 9-10       Impact factor: 1.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.